Shanghai Pharmaceuticals Secures Production Approval for Isavuconazonium Sulfate for Injection
Stock News
Sep 28
Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., recently received a Drug Registration Certificate from the National Medical Products Administration.
The certificate, numbered 2026S03379, grants approval for the production of Isavuconazonium Sulfate for Injection.
The drug is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients and pediatric patients aged 1 year and older.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.